Trevi Therapeutics
NASDAQ: TRVINew Haven, US · Founded 2011 · Delaware corporation · 47 employees on LinkedIn · 4 known investors
Find your way into Trevi Therapeutics
48 people in our graph share verified history with the Trevi Therapeutics team — schools, employers, funds. One of them is your warm intro.
Elizabeth Stonerunlockedknows Jennifer Good · together at Rhythm Pharmaceuticals (overlapped)
knows the team · via Trevi Therapeutics
×2knows the team · via Rhythm Pharmaceuticals
×8knows the team · via Creighton University
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Founders & leadership
Trevi Therapeutics was founded in 2011 by Thomas Sciascia, Jennifer Good, and Thomas Sciascia, M.D..
TS
Thomas SciasciaCo-founder
JG
Jennifer GoodinCo-Founder, President and CEOShe co-founded the company in 2011 after serving as president and CEO of Penwest Pharmaceuticals, where she had earlier spent nearly a decade as chief financial officer. Her earlier career included corporate controller at Penford Products and audit manager at Ernst & Young, and she has served on the board of Rhythm Pharmaceuticals since 2019.
TS
Thomas Sciascia, M.D.Co-Founder, Chief Scientific Officer
LD
Lisa DelfiniinChief Financial Officer2021–2025
WF
William ForbesinChief Development Officer (CDO)2021–2022William Forbes brings more than 30 years of pharmaceutical product development experience, including founding a biotech company and serving as its CEO and President overseeing R&D, medical affairs, and manufacturing. He has contributed to regulatory approvals across multiple therapeutic areas including anti-infectives, gastrointestinal, respiratory, cardiovascular, and oncology, with expertise spanning small molecules, biologics, and drug-device combinations.
MH
JC
James CassellaNamed on SEC filing
DC
Dominick ColangeloNamed on SEC filing
AV
Anne VanLentNamed on SEC filing
Board
EM
Edward MathersBoard director
DM
David MeekerBoard director
Investors · 4
Funding
SEC filings, press & company announcements$121.7M disclosed across 4 of 10 rounds · 1900–2026
- Undisclosed amountunderwritten public offeringApr 2026Source ↗
▶$55MraisedApr 2022 · 12 investors · BiotechnologyRule 506(b)
▶$55MraisedApr 2022 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HeffernanDirector
- Thomas SciasciaExecutive Officer
- David MeekerDirector
- James CassellaDirector
- Dominick ColangeloDirector
- Jennifer L. GoodExecutive Officer, Director
- William ForbesExecutive Officer
- Edward MathersDirector
- Anne VanLentDirector
- Lisa DelfiniExecutive Officer
- Offering amount
- $55M
- Amount sold
- $55M
- Sales commissions
- $3.3M
- Placement agents
- Needham & Company, LLC, Oppenheimer & Co. Inc., Aegis Capital Corp., Stifel, Nicolaus & Company, Incorporated
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedOct 2021 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward MathersDirector
- Michael HeffernanDirector
- Lisa DelfiniExecutive Officer
- James CassellaDirector
- Dominick ColangeloDirector
- Jennifer L. GoodExecutive Officer, Director
- Anne VanLentDirector
- William ForbesExecutive Officer
- Thomas SciasciaExecutive Officer
- David MeekerDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.8MraisedOct 2021 · 1 investors · BiotechnologyRule 506(b)
▶$11.8MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anne VanLentDirector
- Dominick ColangeloDirector
- William ForbesExecutive Officer
- Jennifer L. GoodExecutive Officer, Director
- Edward MathersDirector
- James CassellaDirector
- Lisa DelfiniExecutive Officer
- David MeekerDirector
- Michael HeffernanDirector
- Thomas SciasciaExecutive Officer
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- Sales commissions
- $709K
- Placement agents
- Stifel, Nicolaus & Company, Incorporated, Needham & Company, LLC
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$51.9MraisedSep 2018 · 18 investors · BiotechnologyRule 506(b)
▶$51.9MraisedSep 2018 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas R. SciasciaExecutive Officer
- Michael HeffernanDirector
- Mette Kirstine AggerDirector
- Ed MathersDirector
- Chris SeiterExecutive Officer
- Annie MitsakDirector
- Jennifer L. GoodExecutive Officer, Director
- Eran NadavDirector
- David MeekerDirector
- Offering amount
- $61.9M
- Amount sold
- $51.9M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Seeking Alpha20 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood19 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView19 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks18 shared keywordsFinancial analysis and stock research platform.
Simply Wall St15 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
StockTwits14 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Trevi Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Trevi Therapeutics do?
- Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
- Who founded Trevi Therapeutics?
- Trevi Therapeutics was founded by Thomas Sciascia, Jennifer Good, Thomas Sciascia, M.D. in 2011.
- Who are Trevi Therapeutics's investors?
- Trevi Therapeutics's investors include APERTURE Venture Partners, Frazier Life Sciences, New Enterprise Associates (NEA), Omega Funds.
- How much funding has Trevi Therapeutics raised?
- Trevi Therapeutics has disclosed $121.7M raised across 4 of its 10 known rounds.
- Where is Trevi Therapeutics headquartered?
- Trevi Therapeutics is headquartered in New Haven, US.